X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (11) 11
humans (11) 11
male (11) 11
middle aged (11) 11
aged (9) 9
index medicus (9) 9
cardiovascular diseases (8) 8
diabetes (8) 8
risk factors (8) 8
clinical trials (7) 7
drug therapy (7) 7
type 2 diabetes (7) 7
diabetes mellitus (6) 6
diabetes mellitus, type 2 - drug therapy (6) 6
double-blind method (6) 6
empagliflozin (6) 6
endocrinology & metabolism (6) 6
treatment outcome (6) 6
analysis (5) 5
benzhydryl compounds - therapeutic use (5) 5
diabetes mellitus, type 2 - blood (5) 5
glucosides - therapeutic use (5) 5
hypoglycemic agents - therapeutic use (5) 5
medicine & public health (5) 5
mortality (5) 5
adult (4) 4
cardiovascular disease (4) 4
double-blind (4) 4
heart failure (4) 4
hypertension (4) 4
internal medicine (4) 4
kidney diseases (4) 4
sitagliptin (4) 4
type 2 diabetes mellitus (4) 4
add-on (3) 3
blood pressure - drug effects (3) 3
cardiac & cardiovascular systems (3) 3
cardiology (3) 3
care and treatment (3) 3
diabetics (3) 3
endothelin receptor antagonist (3) 3
glomerular filtration rate - drug effects (3) 3
glycated hemoglobin a - metabolism (3) 3
health aspects (3) 3
health risk assessment (3) 3
health risks (3) 3
patients (3) 3
placebos (3) 3
risk (3) 3
safety (3) 3
saxagliptin (3) 3
time factors (3) 3
3121 internal medicine (2) 2
adults (2) 2
article (2) 2
association (2) 2
benzhydryl compounds - adverse effects (2) 2
biomarkers - blood (2) 2
blood glucose - drug effects (2) 2
blood glucose - metabolism (2) 2
cardiovascular diseases - drug therapy (2) 2
cerebral infarction (2) 2
chronic kidney-disease (2) 2
ckd (2) 2
complications and side effects (2) 2
creatinine (2) 2
creatinine - blood (2) 2
darusentan (2) 2
death (2) 2
diabetes mellitus, type 2 (2) 2
diabetes mellitus, type 2 - diagnosis (2) 2
diabetic nephropathies - diagnosis (2) 2
dosage and administration (2) 2
drug therapy, combination (2) 2
end-point (2) 2
endocrinology (2) 2
epidermal growth factor receptors (2) 2
events (2) 2
gfr decline (2) 2
glomerular filtration rate (2) 2
glucose (2) 2
glucosides - adverse effects (2) 2
glycated hemoglobin a - analysis (2) 2
heart-failure (2) 2
hemoglobin (2) 2
human physiology (2) 2
hypoglycemia (2) 2
hypoglycemia - chemically induced (2) 2
hypoglycemic agents - administration & dosage (2) 2
hypoglycemic agents - adverse effects (2) 2
insulin (2) 2
kidney - drug effects (2) 2
kidney - physiopathology (2) 2
kidney-disease (2) 2
linagliptin (2) 2
long-term (2) 2
metabolic diseases (2) 2
metformin (2) 2
metformin - therapeutic use (2) 2
microvasculature (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetologia, ISSN 0012-186X, 8/2018, Volume 61, Issue 8, pp. 1712 - 1723
Journal Article
Diabetologia, ISSN 0012-186X, 9/2016, Volume 59, Issue 9, pp. 1860 - 1870
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
Journal Article
Quality of Life Research, ISSN 0962-9343, 5/2016, Volume 25, Issue 5, pp. 1199 - 1207
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 03/2018, Volume 17, Issue 1, pp. 39 - 15
Background: Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to... 
Treatment outcome | Diabetes mellitus, type 2 | Dipeptidyl-peptidase IV inhibitors | Diabetic nephropathies | Linagliptin | Research design | Cardiovascular diseases | Clinical trial, phase IV | KIDNEY-DISEASE | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | type 2 | GFR DECLINE | Diabetes mellitus | phase IV | HEART-FAILURE | SITAGLIPTIN | DPP-4 | END-POINT | ENDOCRINOLOGY & METABOLISM | Clinical trial | POOLED ANALYSIS | CKD | EPIDEMIOLOGY | Kidney Failure, Chronic - mortality | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Linagliptin - adverse effects | Diabetic Nephropathies - drug therapy | Male | Linagliptin - therapeutic use | Diabetic Nephropathies - diagnosis | Cause of Death | Renal Insufficiency, Chronic - drug therapy | Glomerular Filtration Rate - drug effects | Time Factors | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Female | Renal Insufficiency, Chronic - diagnosis | Kidney - physiopathology | Cardiovascular Diseases - diagnosis | Kidney Failure, Chronic - physiopathology | Kidney - drug effects | Double-Blind Method | Risk Factors | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Diabetic Nephropathies - mortality | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - mortality | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Research Design
Journal Article
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, ISSN 0931-0509, 09/2019
Doubling of serum creatinine [equivalent to 57% reduction in estimated glomerular filtration rate (eGFR)] is an established surrogate for end-stage kidney... 
Journal Article
Circulation, ISSN 0009-7322, 03/2019, Volume 139, Issue 11, pp. 1384 - 1395
BACKGROUND:In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with... 
carotid artery diseases | sodium-glucose transporter 2 | death, sudden, cardiac | diabetes mellitus, type 2 | cardiovascular diseases | Heart failure | Risk assessment | Analysis | Patient outcomes | Research | Drug therapy | Cardiovascular diseases | Risk factors | 10155 | Original s
Journal Article
Kidney International, ISSN 0085-2538, 01/2018, Volume 93, Issue 1, pp. 231 - 244
Sodium glucose cotransporter 2 (SGLT2) inhibitors reduce HbA1c, blood pressure, and weight in patients with type 2 diabetes. To investigate the effect of renal... 
glomerular filtration rate | kidney diseases | diabetic nephropathy | SGLT2 inhibition | ADD-ON | COTRANSPORTER 2 INHIBITION | AORTIC STIFFNESS | ARTERIAL STIFFNESS | SALT SENSITIVITY | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Diabetic Nephropathies - blood | Weight Loss - drug effects | Diabetic Nephropathies - diagnosis | Clinical Trials, Phase III as Topic | Glomerular Filtration Rate - drug effects | Kidney - metabolism | Benzhydryl Compounds - adverse effects | Diabetic Nephropathies - physiopathology | Adult | Female | Glucosides - therapeutic use | Renal Insufficiency, Chronic - diagnosis | Blood Pressure - drug effects | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Kidney - physiopathology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Kidney - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Down-Regulation | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Randomized Controlled Trials as Topic | Renal Insufficiency, Chronic - blood | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Aged | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
Diabetes Therapy, ISSN 1869-6953, 2/2019, Volume 10, Issue 1, pp. 325 - 326
The authors have updated Fig. 3 which was incorrectly published in the original publication. 
Internal Medicine | Diabetes | Medicine & Public Health | Cardiology | Endocrinology
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A1719 - A1719
Journal Article
Journal Article